Abcam, ab259092, Human RRAS2 (TC21) knockout HEK-293T cell lysate

Size: 1Kit
RRAS2 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 25 bp deletion in exon 11 and 2 bp deletion in exon 11.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 25 bp deletion in exon 11 and 2 bp deletion in exon 11.

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-RRAS2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
TC21 also known as R-Ras2 is a small GTPase with a molecular mass of approximately 23 kDa. It belongs to the Ras superfamily of proteins and plays an important role in signal transduction. TC21 switches between inactive GDP-bound and active GTP-bound states participating in the propagation of signals within the cell. The protein is expressed in a variety of tissues with significant levels found in the brain lung and lymphoid organs. Its activity is tightly regulated through interactions with guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs).
Biological function summary
TC21 influences various cellular processes such as cell growth survival and differentiation. It is active in several signaling pathways contributing to the regulation of cytoskeletal organization and cell adhesion. TC21 is part of larger signaling complexes that engage in mitogenic signaling and influences the function of integrins. These activities position TC21 as a dynamic regulator of cellular behavior allowing it to coordinate and fine-tune responses to extracellular signals.
Pathways
TC21 is integral to the PI3K/AKT and MAPK signaling pathways. In these pathways TC21 interacts with related proteins like PI3K and RAF1 to transmit signals that promote cell proliferation and survival. The PI3K/AKT pathway for instance involves TC21 in the downstream activation of AKT influencing metabolism growth and apoptosis. It also connects with the MAPK pathway contributing to gene expression changes and facilitating cellular responses to growth stimuli.
Alterations in TC21 function link to oncogenic processes including breast cancer and leukemia. Overexpression or mutations in the TC21 gene can lead to abnormal signaling enhancing cell proliferation and resisting apoptosis. In these oncogenic pathways TC21 often partners with other Ras family members like HRAS which cooperate to drive tumorigenesis. Understanding TC21's role in these pathways aids in the development of targeted therapies aiming to disrupt its pathological signaling activities.